MARKET

NBP

NBP

NovaBridge Biosciences
NASDAQ
2.430
-0.030
-1.22%
After Hours: 2.430 0 0.00% 16:10 04/02 EDT
OPEN
2.380
PREV CLOSE
2.460
HIGH
2.570
LOW
2.372
VOLUME
1.52M
TURNOVER
--
52 WEEK HIGH
6.79
52 WEEK LOW
0.5950
MARKET CAP
280.16M
P/E (TTM)
-8.5957
1D
5D
1M
3M
1Y
5Y
1D
NovaBridge Biosciences director Conor Chia-hung Yang files initial beneficial ownership statement
Reuters · 3d ago
Weekly Report: what happened at NBP last week (0323-0327)?
Weekly Report · 5d ago
NovaBridge Biosciences EVP Denny Hsueh Wen Chu Files Initial Beneficial Ownership Statement
Reuters · 03/25 00:08
Weekly Report: what happened at NBP last week (0316-0320)?
Weekly Report · 03/23 10:21
NovaBridge Biosciences CMO Dennis Phillip Andrew Files Initial Beneficial Ownership Statement
Reuters · 03/19 10:18
NovaBridge Biosciences General Counsel Lin Liwei Lorraine Files Initial Beneficial Ownership Statement
Reuters · 03/19 01:45
NovaBridge Biosciences CEO and Director Xi-Yong Fu files Form 3 initial beneficial ownership statement
Reuters · 03/19 01:44
NovaBridge Biosciences files Form 3 reporting Chief Investment Officer Zhang Xiaofan Neo as beneficial owner
Reuters · 03/19 01:41
More
About NBP
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.

Webull offers NovaBridge Biosciences stock information, including NASDAQ: NBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NBP stock methods without spending real money on the virtual paper trading platform.